Clinical Trial Update: XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) for metastatic or advanced melanoma in patients previously treated with immune che…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• XmAb22841
• XmAb23104 (XmAb23104)

Snippet

Sponsor: University of California, San Francisco | Conditions: Metastatic Melanoma, Advanced Melanoma | Phase 1 | Status: TERMINATED